Position in BTAI
as of Dec 31, 2025
· filed Feb 6, 2026
Position Value
$192,163
New position
Shares Held
120,102
first reported quarter
Ownership
0.389%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026GSA CAPITAL PARTNERS LLP holds $10,107,066 across 16 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IRWD |
Ironwood Pharmaceuticals Inc
|
654,445 | $2,297,101 | |
| 2 | LQDA |
Liquidia Corp
|
35,406 | $1,336,222 | |
| 3 | VTRS |
Viatris Inc
|
89,952 | $1,215,251 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
6,688 | $881,077 | |
| 5 | RGC |
Regencell Bioscience Holdings Ltd
|
31,569 | $802,799 | |
| 6 | XERS |
Xeris Biopharma Holdings, Inc.
|
101,438 | $588,340 | |
| 7 | SUPN |
Supernus Pharmaceuticals, Inc.
|
10,556 | $545,639 | |
| 8 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
11,257 | $542,024 |
All Filings in BTAI
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2025-12-31 | $192,163 | 120,102 | Shares | Sole | 2026-02-06 | |
| No filing history on record for this holder in this stock. | ||||||